44 related articles for article (PubMed ID: 29802871)
1. Reliably making the primary diagnosis of mesothelioma utilizing serous fluid cytology specimens: an institutional experience.
Jones TE; Geisler DL; Baskota SU; Ohori NP; Cuda J; Khader SN
J Am Soc Cytopathol; 2024; 13(3):174-182. PubMed ID: 38514361
[TBL] [Abstract][Full Text] [Related]
2. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ
Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416
[TBL] [Abstract][Full Text] [Related]
3. Claudin-4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study.
Hruaii V; Thirunavukkarasu B; Prabha V; Mathur S; Iyer VK; Nambirajan A; Jain D
Diagn Cytopathol; 2024 Jan; 52(1):30-41. PubMed ID: 37837242
[TBL] [Abstract][Full Text] [Related]
4. Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance.
Dos Santos MV; Holth A; Bischof K; Davidson B
Clin Exp Metastasis; 2024 Feb; 41(1):69-76. PubMed ID: 38141113
[TBL] [Abstract][Full Text] [Related]
5. Malignant mesothelioma cells with characteristic intracytoplasmic vacuolization and lipids.
Morito S; Yasui H; Itoh T; Kamoshida S; Ohsaki H
Diagn Cytopathol; 2023 Dec; 51(12):E328-E331. PubMed ID: 37583304
[TBL] [Abstract][Full Text] [Related]
6. Lung cancer tumor markers in serous effusions and other body fluids.
Trapé J; Bérgamo S; González-Garcia L; González-Fernández C
Tumour Biol; 2024; 46(s1):S99-S110. PubMed ID: 36502355
[TBL] [Abstract][Full Text] [Related]
7. Multiple peimary cancers in patient with malignant pleural mesothelioma and ovarian serous carcinoma: A case report.
Tian D; Wang H; Zhu B; Liu H
Asian J Surg; 2024 Mar; ():. PubMed ID: 38480095
[No Abstract] [Full Text] [Related]
8. Role of p16 deletion and BAP1 loss in the diagnosis of malignant mesothelioma.
Liu J; Liao X; Gu Y; Fu L; Zhao J; Li L; Chen Z; Jiang J
J Thorac Dis; 2018 Sep; 10(9):5522-5530. PubMed ID: 30416802
[No Abstract] [Full Text] [Related]
9. The World Health Organization Reporting System for Lung Cytopathology-A Review of the First Edition.
Dolezal D; Kholová I; Cai G
J Clin Transl Pathol; 2024; 4(1):18-35. PubMed ID: 38736711
[TBL] [Abstract][Full Text] [Related]
10. PET-CT-guided
de Fonseka D; Arnold DT; Smartt HJM; Culliford L; Stadon L; Tucker E; Morley A; Zahan-Evans N; Bibby AC; Lynch G; Mishra E; Khan S; Haris M; Steer H; Lewis L; Ionescu A; Harvey J; Blyth K; Rahman NM; Edey AE; Rogers CA; Maskell NA
Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38097208
[TBL] [Abstract][Full Text] [Related]
11. Ancillary Diagnostic Investigations in Malignant Pleural Mesothelioma.
Dipper A; Maskell N; Bibby A
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34209209
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for Regulated Cell Death Assays: A Systematic Summary, A Categorical Comparison, A Prospective.
Hu XM; Li ZX; Lin RH; Shan JQ; Yu QW; Wang RX; Liao LS; Yan WT; Wang Z; Shang L; Huang Y; Zhang Q; Xiong K
Front Cell Dev Biol; 2021; 9():634690. PubMed ID: 33748119
[TBL] [Abstract][Full Text] [Related]
13. Pleural mesothelioma classification update.
Beasley MB; Galateau-Salle F; Dacic S
Virchows Arch; 2021 Jan; 478(1):59-72. PubMed ID: 33475835
[TBL] [Abstract][Full Text] [Related]
14. Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
Chapel DB; Schulte JJ; Husain AN; Krausz T
Transl Lung Cancer Res; 2020 Feb; 9(Suppl 1):S3-S27. PubMed ID: 32206567
[TBL] [Abstract][Full Text] [Related]
15. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.
Yatabe Y; Dacic S; Borczuk AC; Warth A; Russell PA; Lantuejoul S; Beasley MB; Thunnissen E; Pelosi G; Rekhtman N; Bubendorf L; Mino-Kenudson M; Yoshida A; Geisinger KR; Noguchi M; Chirieac LR; Bolting J; Chung JH; Chou TY; Chen G; Poleri C; Lopez-Rios F; Papotti M; Sholl LM; Roden AC; Travis WD; Hirsch FR; Kerr KM; Tsao MS; Nicholson AG; Wistuba I; Moreira AL
J Thorac Oncol; 2019 Mar; 14(3):377-407. PubMed ID: 30572031
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers in the diagnosis of pleural diseases: a 2018 update.
Porcel JM
Ther Adv Respir Dis; 2018; 12():1753466618808660. PubMed ID: 30354850
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic role of BAP1 in serous effusions.
Davidson B; Tötsch M; Wohlschlaeger J; Hager T; Pinamonti M
Hum Pathol; 2018 Sep; 79():122-126. PubMed ID: 29802871
[TBL] [Abstract][Full Text] [Related]
18. MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions.
Davidson B; Stavnes HT; Hellesylt E; Hager T; Zeppa P; Pinamonti M; Wohlschlaeger J
Hum Pathol; 2016 Jan; 47(1):104-8. PubMed ID: 26520416
[TBL] [Abstract][Full Text] [Related]
19. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
